These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1362474)

  • 1. Treatment with neuroleptics: the patient's perspective.
    Windgassen K
    Acta Psychiatr Scand; 1992 Nov; 86(5):405-10. PubMed ID: 1362474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subjective response to neuroleptics: the effect of a questionnaire about neuroleptic side effects.
    Taira M; Hashimoto T; Takamatsu T; Maeda K
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1139-42. PubMed ID: 16765499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subjective utility ratings of neuroleptics in treating schizophrenia.
    Finn SE; Bailey JM; Schultz RT; Faber R
    Psychol Med; 1990 Nov; 20(4):843-8. PubMed ID: 1980954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome.
    Awad AG; Voruganti LN; Heslegrave RJ; Hogan TP
    Int Clin Psychopharmacol; 1996 May; 11 Suppl 2():55-9. PubMed ID: 8803661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurological soft signs in neuroleptic-naive and neuroleptic-treated schizophrenic patients and in normal comparison subjects.
    Gupta S; Andreasen NC; Arndt S; Flaum M; Schultz SK; Hubbard WC; Smith M
    Am J Psychiatry; 1995 Feb; 152(2):191-6. PubMed ID: 7840351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Viewpoint of schizophrenic patients: a European survey].
    Courtet P
    Encephale; 2001; 27(1):28-38. PubMed ID: 11294036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subjective well-being, drug attitude, and changes in symptomatology in chronic schizophrenia patients starting treatment with new-generation antipsychotic medication.
    Widschwendter CG; Kemmler G; Rettenbacher MA; Yalcin-Siedentopf N; Hofer A
    BMC Psychiatry; 2018 Jun; 18(1):212. PubMed ID: 29954366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rating of medication influences (ROMI) scale in schizophrenia.
    Weiden P; Rapkin B; Mott T; Zygmunt A; Goldman D; Horvitz-Lennon M; Frances A
    Schizophr Bull; 1994; 20(2):297-310. PubMed ID: 7916162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic treatment with neuroleptics. II: Subjective mechanisms of effect, compliance and consequences for treatment strategy].
    Krausz M; Sorgenfrei T
    Psychiatr Prax; 1991 Jan; 18(1):14-20. PubMed ID: 1674155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The meaning and management of neuroleptic medication: a study of patients with a diagnosis of schizophrenia.
    Rogers A; Day JC; Williams B; Randall F; Wood P; Healy D; Bentall RP
    Soc Sci Med; 1998 Nov; 47(9):1313-23. PubMed ID: 9783874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects and side effects of antipsychotic treatment in schizophrenia: pros and cons of available self-rating scales.
    Wolters HA; Knegtering H; van den Bosch RJ; Wiersma D
    Schizophr Res; 2009 Jul; 112(1-3):114-8. PubMed ID: 19395241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schizophrenic patients' experiences of neuroleptic medication: a Q-methodological investigation.
    Day JC; Bentall RP; Warner S
    Acta Psychiatr Scand; 1996 May; 93(5):397-402. PubMed ID: 8792911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Changes in the health state of schizophrenic patients in neuroleptic therapy].
    Heim M
    Psychiatr Neurol Med Psychol (Leipz); 1986 Aug; 38(8):483-7. PubMed ID: 2878452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia.
    Gur RE; Maany V; Mozley PD; Swanson C; Bilker W; Gur RC
    Am J Psychiatry; 1998 Dec; 155(12):1711-7. PubMed ID: 9842780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Patient modified medication: how do schizophrenic patients manage their neuroleptics?].
    Hornung WP; Buchkremer G; Redbrake M; Klingberg S
    Nervenarzt; 1993 Jul; 64(7):434-9. PubMed ID: 8103569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives.
    Ascher-Svanum H; Nyhuis AW; Stauffer V; Kinon BJ; Faries DE; Phillips GA; Schuh K; Awad AG; Keefe R; Naber D
    Curr Med Res Opin; 2010 Oct; 26(10):2403-10. PubMed ID: 20812791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depressive states occurring during the neuroleptic treatment of schizophrenia.
    Möller HJ; von Zerssen D
    Schizophr Bull; 1982; 8(1):109-17. PubMed ID: 6122264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmaco-epidemiological study on antipsychotic drug prescription in French Psychiatry: Patient characteristics, antipsychotic treatment, and care management for schizophrenia].
    Brunot A; Lachaux B; Sontag H; Casadebaig F; Philippe A; Rouillon F; Cléry-Melin P; Hergueta T; Llorca PM; Moreaudefarges T; Guillon P; Lebrun T
    Encephale; 2002; 28(2):129-38. PubMed ID: 11972139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
    Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
    J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment.
    Löffler W; Kilian R; Toumi M; Angermeyer MC
    Pharmacopsychiatry; 2003 May; 36(3):105-12. PubMed ID: 12806568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.